Search the web
Welcome, Guest
[Sign Out, My Account]

Friday, August 26 2016 9:36pm ET - U.S. Markets Closed.
Industry Center - Drug Manufacturers - Other
Industry Center > Drug Manufacturers - Other
More On This Industry
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Related Products
· Drugs - Generic
Top Industries
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Diversified Utilities
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
·Tobacco Products, Other
Complete Industry List...
Morningstar Inc.
In-depth Company Dossier Reports on over 7,500 publicly traded U.S. companies. Click here for your free report.
Industry Market Summary
Drug Manufacturers - Other
Composite Value: 919.3
Today's Change: +0.02%
S&P 500: -0.27%
chart for
[Drug Manufacturers - Other (^YHOh784)]
Drug Manufacturers - Other News
RegeneRx Joint Venture to Begin Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome in 3rd Quarter
Wed Aug 24 (PR Newswire)
ROCKVILLE, Md., Aug. 24, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture, ReGenTree, LLC, has received permission from the U.S. FDA to proceed with a second Phase 3 clinical trial using RGN-259 to treat patients with dry eye syndrome (DES). ReGenTree, LLC, a joint venture company between RegeneRx and GtreeBNT, a Korean Biopharmaceutical Company, officially received a confirmatory response from the FDA for its second Phase 3 protocol and overall development plan of RGN-259, a new drug candidate to treat dry eye syndrome (DES).
Cumberland Pharmaceuticals Begins U.S. Shipments Of Ethyol® (amifostine) For Oncology Patient Support - (PR Newswire)
Taro Announces Completion of $250 Million Share Repurchase Program - (Business Wire)
More News on Drug Manufacturers - Other: Latest News,
Industry Top Performers
Intraday Price Performance% ChangeMarket Cap
More Top Intraday Price Performers...
Market Capitalization% ChangeMarket Cap
Novo Nordisk A/S Common Stock [NVO] -0.21% $118.9 B
Teva Pharmaceutical Industries [TEVA] +0.27% $47.2 B
Dr. Reddy's Laboratories Ltd Co [RDY] -0.57% $7.5 B
Isis Pharmaceuticals, Inc. [ISIS] 0.00% $6.9 B
Taro Pharmaceutical Industries [TARO] +1.16% $5.5 B
More Top Companies by Market Cap...
More Top Performers: by Valuation, by Growth, by Financial Strength
Industry Calendar
Recent Events
Date Co Event
08/12/16 ENDP Endo International plc upgraded by Mizuho
08/12/16 PTX Pernix Therapeutics Holdings, I downgraded by Brean Capital
08/11/16 PTX Pernix Therapeutics Holdings, I downside earnings surprise (-487.50%)
More Recent Events...
Locate Industry by Company
Enter Symbol:
Industry Statistics
Market Capitalization:194B
Price / Earnings:27.9
Price / Book:65.9
Net Profit Margin (mrq):18.5%
Price To Free Cash Flow (mrq):-92.0
Return on Equity:20.6%
Total Debt / Equity:22.0
Dividend Yield:2.8%
View Industry Browser
Community Spotlight
Most Active Boards
Board Popularity
Unusually Active Boards
Board Variance

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Manufacturers - Other Headlines
More Finance RSS Feeds

Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2016 Morningstar, Inc. All Rights Reserved. Company information © 2016 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?